Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IL-2 With or Without TNF Antagonist in HIV-1 Infection
NCT00001475Phase 2Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Jun 1995
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 2, randomised trial of aldesleukin in human immunodeficiency virus infection (HIV) (7 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Safety and tolerability of the IL-2/TNF inhibitor combination at 1 year, Frequency of IL-2 associated fatigue and fever at 1 year and 2 more. Started Jun 1995; status: completed.
02
Drugs
aldesleukin
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT00001475.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00001475.